Synthesis of stable isotopically labelled internal standards for drug-drug interaction (DDI) studies

被引：0
|
作者：
Zimmermann, J. [1 ]
Allen, J. [2 ]
Atzrodt, J. [1 ]
De-Bruin, B. [2 ]
Derdau, V. [1 ]
Gantz, D. [1 ]
Herbert, J. [3 ]
Raddatz, S. [1 ]
Roy, S. [2 ]
机构：
[1] Sanofi Aventis, Global Isotope Chem & Metabollite Synthet Dept, D-65926 Frankfurt, Germany
[2] Sanofi Aventis, Global Isotope Chem & Metabollite Synthet Dept, F-91385 Chilly Mazarin, France
[3] Sanofi Aventis, Global Isotope Chem & Metabollite Synthet Dept, Ainwick NE66 2JH, England
来源：
JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS | 2007年 / 50卷 / 13-14期
关键词：
D O I：
暂无
中图分类号：
Q5 [生物化学];
学科分类号：
071010 ; 081704 ;
摘要：
引用
收藏
页码：1277 / 1278
页数：2
相关论文
共 50 条
  • [1] Synthesis of stable isotope labelled internal standards for drug-drug interaction (DDI) studies
    Atzrodt, J.
    Blankenstein, J.
    Brasseur, D.
    Calvo-Vicente, S.
    Denoux, M.
    Derdau, V.
    Lavisse, M.
    Perard, S.
    Roy, S.
    Sandvoss, M.
    Schofield, J.
    Zimmermann, J.
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY, 2012, 20 (18) : 5658 - 5667
  • [2] A survey of drug-drug interaction (DDI) studies.
    Marroum, P
    Burnett, A
    Svadjian, R
    Uppoor, RS
    Ajayi, F
    Yuan, R
    Lesko, LJ
    Balian, JD
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1998, 63 (02) : 147 - 147
  • [3] Most common interactant drugs in drug-drug interaction (DDI) studies.
    Uppoor, RS
    Marroum, P
    Burnett, A
    Ajayi, F
    Yuan, R
    Svadjian, R
    Balian, JD
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1998, 63 (02) : 147 - 147
  • [4] Role of in vitro metabolic interactions in the conduct of drug-drug interaction (DDI) studies.
    Yuan, R
    Balian, JD
    Svadjian, R
    Uppoor, RS
    Ajayi, F
    Burnett, A
    Lesko, LJ
    Marroum, P
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1998, 63 (02) : 218 - 218
  • [5] Drug-Drug Interaction (DDI) Due to the Inhibition of Fusidic Acid
    Shi, Yun
    [J]. LATIN AMERICAN JOURNAL OF PHARMACY, 2017, 36 (09): : 1736 - 1738
  • [6] Drug-Drug Interaction (DDI) of Eslicarbazepine Acetate with Antiepileptic Drugs
    Blum, David
    Nunes, Teresa
    Maier, Gary
    Versavel, Mark
    Zummo, Jacqueline
    Kharidia, Jahnavi
    Soares-da-Silva, Patricio
    [J]. NEUROLOGY, 2011, 76 (09) : A287 - A287
  • [7] Lung Cancer Drug-Drug Interaction (DDI) Related with Praeruptorin D
    Li, Ke
    Zhou, Ning
    [J]. LATIN AMERICAN JOURNAL OF PHARMACY, 2017, 36 (01): : 184 - 187
  • [8] Drug-drug interaction (DDI) potential of oral napabucasin in healthy adults
    Dai, Xiaoshu
    Karol, Michael D.
    Hitron, Matthew
    Hard, Marjie
    Goulet, Matthew T.
    Mclaughlin, Colleen F.
    Brantley, Scott J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [9] Use of simple stable labelled intermediates to produce complex isotopically labelled internal standards
    Allen, Paul
    Hickey, Mike
    Kingston, Lee
    Mather, Andrew
    Wilkinson, David J.
    [J]. JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS, 2007, 50 (5-6): : 590 - 592
  • [10] DDI-Transform: A neural network for predicting drug-drug interaction events
    Su, Jiaming
    Qian, Ying
    [J]. QUANTITATIVE BIOLOGY, 2024, 12 (02) : 155 - 163
12345